期刊
INTERNATIONAL REVIEWS OF IMMUNOLOGY
卷 33, 期 5, 页码 417-427出版社
TAYLOR & FRANCIS INC
DOI: 10.3109/08830185.2014.911855
关键词
adhesion; drug resistance; galectins; multiple myeloma; NF-kappa B; ovarian cancer
类别
资金
- Rush Endowed Chair for Excellence in Women's Health and Oncology, the Division of Hematology Oncology, Kiromic LLC
- Endowed Chair for Excellence in Women's Health Director of Breast Health Service
Here we review the role of Galectins in the molecular pathogenesis of multiple myeloma and ovarian cancer, with a special focus on Glectin-3. Multiple myeloma is the second most common hematologic malignancy worldwide. Because the pathogenesis of multiple myeloma is still incompletely understood, there is no ultimately effective cure, and this cancer results fatal. Ovarian cancer is the most lethal gynecologic malignancy worldwide. Due to the lack of screening techniques for early detection, patients are mostly diagnosed with advanced disease, which results ultimately fatal. Multiple myeloma and ovarian cancer have different biologies, but they share a strong dependence on adhesion with extracellular matrix and other cells. Galectin-3 plays a key role in regulating such adhesive abilities of tumor cells. Here we discuss the outcomes and possible mechanism of action of a truncated, dominant negative form of Galectin-3, Galectin-3C, in these malignancies. Overall, we report that Galectin-3C is a promising new compound for effective adjuvant therapies in advanced, refractory multiple myeloma and ovarian cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据